Skip to content
naulon

Not checkedNot checked for notices yet.

Research Progress of Immunotherapy for Non-small Cell Lung Cancer with Drive Gene Mutation

Renfang DENG, Yue ZENG, Yue PAN and 2 more

Chinese Journal of Lung Cancer · 2022

doi:10.3779/j.issn.1009-3419.2022.102.06 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Lung cancer is the most lethal malignancy around the world and non-small cell lung cancer (NSCLC) accounts for 80% of all cases. Most of the NSCLC patients has “driver gene mutations” and targeted therapy achieved a relatively good efficacy, but some patients progressed or relapsed after treatment. Previous studies demonstrated that immune checkpoint inhibitor could improve the prognosis of advanced-stage NSCLC and prolong the survival time. However, the efficacy of immune therapy varies in NSCLC patients with different immune and molecular features. The efficacy of immune therapy was controversial in NSCLC patients with driver gene mutation. The present review will summarize the immune characteristics of NSCLC patients with driver mutation and the directions of immunotherapy for patients with driver mutation.

Abstract licence: CC BY

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.